Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Expanded Program on Immunization


Background and Definition
Expanded Program on Immunization (EPI), established in 1987, aimes at guaranteeing the right of every child in Lebanon, regardless of social status or parent's education level, on immunization and protection from diseases that have available effective and safe vaccines. In order to ensure that, the Ministry of Public Health guarantees the provision of vaccines in  700 health care centers, public and social, in collaboration with the private sector and with the conitnuous awareness of care givers about the importance of immunization. The program provides further special attention to chidlren residing in remote and underprivileged areas through quality outreach activities.
 
EPI ِAims at:
  1. Elevating routine vaccination coverage per district to above 95%.
  2. Preserving Lebanon as polio-free, considering the continuous influx of Syrian refugees and in preparation to the eradication of polio in the region and worldwide.
  3. Eradicating Measles and Rubella by the end of year 2018.
 
EPI Activities:
  1. Continuous training and capacity building throughout the year for health care workers on routine vaccination management and implementation in all districs.
  2. Continuous work to keep Lebanon certified polio-free
  3. Implementation of the RED STRATEGY to reach every child, which includes:
    1. Data on the immunization coverage for children under one year of age
    2. Data on immunization coverage in Lebanon
    3. Identification of the number of drop-outs and planning to ensure their vaccination per district accordingly
  4. Celebrating World Immunization Week and planning awareness sessions over Lebanon about routine vaccination 
  5. Conducting National and Mop-Up Immunization campaigns annually, including vaccination against Measles, Rubella, and Mumps
  6. Conducting regular visits by the self-assessment team to follow on the quality of vaccination delivery service 
  7. Continuous collaboration with UNICEFand WHO to follow-up on updates related to immunization worldwide and ensuring implementation in Lebanon considering national and international commitments
  8. Continuous collaboration with the private sector (General Practictioners and Pediatricians) to ensure vaccination for all children in Lebanon, particularly during immunization campaigns and routine immunization.
     
    ...
    29
    ...
ATC Name B/G Ingredients Dosage Form Price
J07AL02 VAXNEUVANCE B Pneumococcal polysaccharide for serotypes 1, 3, 4, 5 , 6A, 7F, 9V,14, 18C, 19A, 19F, 22F, 23F,33F (2mcg) Pneumococcal polysaccharide for serotypes 6B (4.4mcg) Conjugated to CRM197 carrier protein and adsorbed on aluminium phosphate adjuvant - Injectable suspension 6,988,413 L.L
L01EC01 ZELBORAF B Vemurafenib - 240mg 240mg Tablet, film coated 142,041,587 L.L
N03AG04 SABRIL B Vigabatrin - 500mg 500mg Tablet, film coated 2,988,706 L.L
N05AX13 TREVICTA B Paliperidone - 350mg 350mg Injectable suspension, prolonged release 50,113,451 L.L
A02BX13 GAVISCON DOUBLE ACTION B Sodium alginate - 500mg, Sodium bicarbonate - 213mg, Calcium (carbonate) - 325mg Suspension 645,044 L.L
C05CA03 DIOVENOR 600 B Diosmin - 600mg 600mg Tablet 544,256 L.L
C10AA07 CRESTOR B Rosuvastatin (calcium) - 5mg 5mg Tablet 589,947 L.L
G04BX14 PRILIGY B Dapoxetine (hydrochloride) - 30mg 30mg Tablet, film coated 1,957,979 L.L
J07AP03 TYPHIM VI B Salmonella typhi polysaccharides - 0.025mg/0.5ml 0.025mg/0.5ml Injectable solution 1,118,077 L.L
N05AX13 TREVICTA B Paliperidone - 525mg 525mg Injectable suspension, prolonged release 75,169,610 L.L
A02BX13 GAVISCON PEPPERMINT LIQUID B Sodium alginate - 250mg/10ml, Sodium bicarbonate - 133.5mg/10ml, Calcium (carbonate) - 80mg/10ml Suspension 393,746 L.L
J07AP03 TYPHIBEV TYPHOID CONJUGATED VACCINE (MONOVALENT) B Salmonella typhi polysaccharides Vi purified - 25mcg of Vi-PS2/0.5ml Injectable suspension 4,020,777 L.L
N05AX13 BYANNLI B Paliperidone - 1000mg 1000mg Injectable suspension, prolonged release 141,223,863 L.L
A03A SPASMOBROM B Pipethanate Ethobromide - 20mg 20mg Tablet, coated 705,517 L.L
C09CA08 OLMETEC B Olmesartan medoxomil - 10mg 10mg Tablet, film coated 710,893 L.L
J01MA06 NOROXIN B Norfloxacin - 400mg 400mg Tablet, film-scored 574,653 L.L
J07AX URO-VAXOM B Lyophilized bacterial lysates of E-Coli - 6mg 6mg Capsule 2,689,029 L.L
L01ED01 XALKORI B Crizotinib - 250mg 250mg Capsule 347,644,061 L.L
N05AX13 BYANNLI B Paliperidone - 700mg 700mg Injectable suspension, prolonged release 96,913,302 L.L
A03AA04 DUSPATALIN RETARD B Mebeverine HCl - 200mg 200mg Capsule 895,581 L.L
A10BA02 GLUCOPHAGE B Metformin HCl - 850mg 850mg Tablet, film coated 572,634 L.L
C09CA08 VOTUM B Olmesartan medoxomil - 10mg 10mg Tablet, film coated 753,896 L.L
D10BA01 ROACCUTANE B Isotretinoin - 20mg 20mg Capsule 2,354,412 L.L
J01DC02 ZINNAT B Cefuroxime (axetil) - 250mg 250mg Tablet, film coated 349,399 L.L
J01MA12 TAVANIC 500MG B Levofloxacin - 500mg/100ml 500mg/100ml Injectable solution 1,988,887 L.L
J07AX BRONCHO-VAXOM CHILDREN B Lyophilized bacterial lysates of Haemophilus influenzae, Diplococcus pneumoniae, Klebsiella pneumoniae and ozaenae, Staphylococcus aureus, Streptococcus pyogenes and viridans, Neisseria catarrhalis - 3.5mg Capsule 1,988,887 L.L
L01ED01 XALKORI B Crizotinib - 200mg 200mg Capsule 347,644,061 L.L
N03AX09 LAMICTAL B Lamotrigine - 100mg 100mg Tablet 2,741,209 L.L
R05D 123 COLD AND FLU B Phenylephrine HCl - 5mg, Carbinoxamine HCl - 3mg, Caffeine anhydrous - 30mg, Codeine phosphate - 8mg, Acetaminophen - 325mg Tablet 409,552 L.L
S02D CERULYSE B Xylene - 5g/100g 5g/100g Drops solution 339,992 L.L
    ...
    29
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2026